443141-90-0

Basic information

• Product Name: 1H-Pyrazole-3-carboxylic acid, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-, hydrazide
• CAS NO: 443141-90-0
• Molecular Formula: C17H13Cl3N4O
• Molecular Weight: 395.675
• Mol File: 443141-90-0.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 1H-Pyrazole-3-carboxylic acid, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-, hydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazole-3-carboxylic acid, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-, hydrazide(443141-90-0)
• EPA Substance Registry System: 1H-Pyrazole-3-carboxylic acid, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-, hydrazide(443141-90-0)

Safety Data

• Hazardous Substances Data: 443141-90-0(Hazardous Substances Data)

Upstream product

• 158941-22-1 ethyl 1-(2,4-dichlorophenyl)-4-methyl-5-(4-chlorophenyl)-1H-pyrazole-3-carboxylate 
• 168273-05-0 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbonyl chloride 

Downstream Products

• 906541-15-9 5-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl]-1,3,4-oxadiazol-2-amine 
• 1040405-33-1 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid(2,6-benzotriazolyl-piperidin-1-yl)amide 
• 1020795-88-3 C₂₄H₂₃Cl₃N₄O₂ 
• 1020795-72-5 C₂₂H₂₁Cl₃N₄O₂ 
• 1016557-47-3 N-butanoyl-N'-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbonyl]-hydrazine 
• 1020804-81-2 C₂₂H₁₆Cl₃F₃N₄O₂ 
• 1020796-92-2 C₂₃H₂₃Cl₃N₄O₂ 
• 1020800-67-2 C₂₇H₂₀Cl₄N₄O₂ 
• 1020801-53-9 C₂₇H₂₂Cl₄N₄O₂ 
• 1020797-32-3 C₂₅H₂₅Cl₃N₄O₂ 
• 1020797-00-5 C₂₅H₂₅Cl₃N₄O₂ 
• 1020800-97-8 C₂₇H₂₁Cl₃N₄O₂ 
• 1020798-75-7 C₂₆H₂₁Cl₃N₄O₂ 
• 1020801-46-0 C₂₇H₂₃Cl₃N₄O₂ 

Relevant articles and documents

Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent antitubercular agents

The structural similarity between an MmpL3 inhibitor BM212, and a cannabinoid receptor modulator rimonabant, prompted us to investigate the anti-tubercular activity of rimonabant and its analogues. Further optimization, particularly through incorporation of silicon into the scaffold, resulted in new compounds with significant improvement in anti-tubercular activity against Mycobacterium tuberculosis (H37Rv). The sila analogue 18a was found to be the most potent antimycobacterial compound (MIC, 31?ng/mL) from this series with an excellent selectivity index.

Pentacycle derivatives as cannabinoid CB1 receptor ligands

Cannabinoid CB-1 receptors have been the focus of extensive studies since the first clinical results of rimonabant (SR141716) for the treatment of obesity and obesity-related metabolic disorders were reported in 2001. To further evaluate the properties of

Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity

Since the CB1 cannabinoid receptor antagonist 1 (SR141716, rimonabant) was previously reported to modulate food intake, CB1 antagonism has been considered as a new therapeutic target for the treatment of obesity. In the present study, biarylpyrazole analo